Lifecare ASA

AGM Information • Sep 3, 2024

LIFECARE ASA: Extraordinary General Meeting

LIFECARE ASA: Extraordinary General Meeting

Lifecare ASA, a clinical stage medical sensor company developing the next

generation Continuous Glucose Monitor (CGM), will hold an Extraordinary

General Meeting 17 September 2024, at 09:00 (CEST).

For the planned uplisting from Euronext Growth Oslo to Oslo Børs, a share

consolidation is required to meet the NOK 10 per share listing requirement.

Additionally, to address shareholders with fractional shares

post-consolidation, the Board proposes General Meeting's approval to acquire

treasury shares.

The notice with complete agenda and documents is available on

https://lifecare.no/events/.

The meeting will be available here:

(https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzRkYWIyMjItYTU2MC00MGMwLTk3NDEtNTE4ZTZlYTk2NzRh%40thread.v2/0?context={"Tid"%3a"c5fbb1c6-4eb0-45db-9f3c-6e20ebcd710e"%2c"Oid"%3a"71082610-7009-40ed-92e6-70ae6bc35450"})

https://teams.microsoft.com/l/meetup-join/19%3ameeting_MzRkYWIyMjItYTU2MC00MGMwLTk3NDEtNTE4ZTZlYTk2NzRh%40thread.v2/0?context=%7b%22Tid%22%3a%22c5fbb1c6-4eb0-45db-9f3c-6e20ebcd710e%22%2c%22Oid%22%3a%2271082610-7009-40ed-92e6-70ae6bc35450%22%7d

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-09-03 14:31 CEST.